Skip to main content
OpenTrials
Recruiting

NCT Number: NCT00327860

Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)

The Division of Kidney, Urologic, and Hematologic Diseases (DKUHD) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Heart, Lung and Blood Institute (NHLBI) funded a cooperative agreement including two Clinical Coordinating Centers (at Children's Hospital of Philadelphia and at Children's Mercy Hospital in Kansas City), a central biochemistry laboratory (at the University of Minnesota) and a Data Coordinating Center (at Johns Hopkins School of Public Health) to conduct a prospective epidemiological study of children with chronic kidney disease (CKD).

Recruiting

Interested in participating?

Request Info

Key information

Age range

6 month–22 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Children's Mercy Kansas City, Kansas City, Missouri, United States

Loading trial locations.

About this study

Since its inception in 2003, the scientific aims of CKiD have been to determine the risk factors for decline in kidney function and to define how progressive decline in kidney function impacts biomarkers of risk factors for cardiovascular disease; neurocognitive function and behavior; and growth failure and its associated morbidity.

The goals have been extended to understand the impact of childhood CKD on: the risk factors for decline in kidney function in childhood and young adulthood; the development of cardiovascular disease in adolescence and young adulthood; the trajectories of markers of metabolic bone disease and the relationship to cardiovascular endpoints; and the social function, neurocognitive function and emotional well-being of adolescents and young adults and the relationship to successful transfer to adult nephrology care.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 1 and 16 years (before 17th birthday) for Cohorts 1 and 2; age between 6 months and 16 years (before 17th birthday) for Cohort 3; age between 16 to 22 years (before 23rd birthday) for Cohort 4
  • Estimated (based on SCr) Schwartz GFR between 30 and 90 ml/min|1.73m2 for Cohort 1 OR an estimated GFR between 45 and 90 ml/min|1.73m2 based on the updated Schwartz formula for Cohort 2; an estimated GFR ≤60 based on the CKiD Under 25 estimating equation (U25eGFR) OR KRT experience (dialysis or transplant) for Cohort 4
  • Willingness and ability to provide informed consent and assent
  • For Cohort 3, children with non-glomerular diagnosis and duration of kidney disease less than 5 years will be enrolled.

Exclusion criteria

  • Solid organ (other than kidney), bone marrow or stem cell transplantation
  • Cancer diagnosis and receiving treatment or within 12 months post completion of treatment
  • Ongoing monitoring for cardiotoxic effects of prior chemotherapy or targeted cancer therapies (e.g., anthracyclines, trastuzumab)
  • HIV infection with detectable viral load despite current antiretroviral therapy
  • Current pregnancy or pregnancy within past twelve months
  • Inability to complete major data collection procedures
  • Not fluent in English or Spanish
  • Plans to move out of area of any participating CKiD site (families can be transferred to another CKiD site if the family moves)
  • Existing moderate to severe congenital structural heart disease
  • Genetic syndromes involving the central nervous system (e.g., Downs syndrome)
  • History of severe to profound intellectual disability (i.e., Intelligence Quotient (IQ)<40, significant impairment in adaptive function and/or inability to independently execute self-care skills)
  • For cohort 3, children who are expected to receive renal replacement therapy within 6 months of date of enrollment will not be recruited

Treatment and study plan

Primary outcomes

  1. Time to Kidney Replacement Therapy

    Time frame: Annually up to 5 years

    The time to Kidney Replacement Therapy (KRT) is assessed as the date of diagnosis to the date of KRT. The exact KRT date is self-reported by the participant and confirmed by medical record abstraction.

Secondary outcomes

  1. Decline in Glomerular filtration rate (GFR) ml/min

    Time frame: Up to 25 years

    Define and identify novel and traditional risk factors for the accelerated decline of GFR at regular annual study visits.

  2. Decline in GFR and risk of cardiovascular disease progression

    Time frame: Up to 25 years

    Analyze the association between decline in GFR and risk of progression of cardiovascular disease at regular annual study visits.

Study contacts

Contact information is provided by the study sponsor or research team.

Bradley Warady, MD

CONTACT

[email protected]

816-302-3010

Susan Furth, MD, PhD

CONTACT

[email protected]

215-590-2449

Sponsors and collaborators

Lead sponsor

Johns Hopkins Bloomberg School of Public Health

Other

Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  • National Heart, Lung, and Blood Institute (NHLBI)
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registry information

Acronym: CKiD

Important dates

Study start
2003
Primary completion
2028
Study completion
2028
First posted
May 19, 2006
Registry last updated
Apr 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.